0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Presidential Address | 
Ashby C. Moncure, MD
Arch Surg. 2001;136(4):376-382. doi:10.1001/archsurg.136.4.376.

Sign in

Purchase Options

• Subscribe to the journal

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Neurology
Editorial  | 
Treatment Decisions for Patients With Active Multiple Sclerosis
Olaf Stüve, MD, PhD; Diego Centonze, MD, PhD
JAMA Neurology
Original Investigation  | 
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
Anna He, MBBS; Tim Spelman, MBBS, MSc; Vilija Jokubaitis, PhD; et al.
JAMA Neurology
Original Investigation  | 
Association of Cerebrospinal Fluid Levels of Lateral Olfactory Tract Usher Substance (LOTUS) With Disease Activity in Multiple Sclerosis
Keita Takahashi, MD; Yuji Kurihara, PhD; Yume Suzuki, MD, PhD; et al.
JAMA Neurology
Editorial  | 
Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?
Jaime Imitola, MD; Michael K. Racke, MD